Three-Month Tolerability of Orlistat in Adolescents with Obesity-Related Comorbid Conditions
Article first published online: 6 SEP 2012
2002 North American Association for the Study of Obesity (NAASO)
Volume 10, Issue 7, pages 642–650, July 2002
How to Cite
McDuffie, J. R., Calis, K. A., Uwaifo, G. I., Sebring, N. G., Fallon, E. M., Hubbard, V. S. and Yanovski, J. A. (2002), Three-Month Tolerability of Orlistat in Adolescents with Obesity-Related Comorbid Conditions. Obesity Research, 10: 642–650. doi: 10.1038/oby.2002.87
- Issue published online: 6 SEP 2012
- Article first published online: 6 SEP 2012
- Submitted for publication November 14, 2001. Accepted for publication in final form February 21, 2002
- weight loss;
Objective: To study the safety, tolerability, and potential efficacy of orlistat in adolescents with obesity and its comorbid conditions.
Research Methods and Procedures: We studied 20 adolescents (age, 14.6 ± 2.0 years; body mass index, 44.1 ± 12.6 kg/m2). Subjects were evaluated before and after taking orlistat (120 mg three times daily) and a multivitamin for 3 months. Subjects were simultaneously enrolled in a 12-week program emphasizing diet, exercise, and strategies for behavior change.
Results: Participants who completed treatment (85%) reported taking 80% of prescribed medication. Adverse effects were generally mild, limited to gastrointestinal effects observed in adults, and decreased with time. Three subjects required additional vitamin D supplementation despite the prescription of a daily multivitamin containing vitamin D. Weight decreased significantly (−4.4 ± 4.6 kg, p < 0.001; −3.8 ± 4.1% of initial weight), as did body mass index (−1.9 ± 2.5 kg/m2; p < 0.0002). Total cholesterol (−21.3 ± 24.7 mg/dL; p < 0.001), low-density lipoprotein-cholesterol (−17.3 ± 15.8 mg/dL; p < 0.0001), fasting insulin (−13.7 ± 19.0 μU/mL; p < 0.02), and fasting glucose (−15.4 ± 7.4 mg/dL; p < 0.003) were also significantly lower after orlistat. Insulin sensitivity, assessed by a frequently sampled intravenous glucose-tolerance test, improved significantly (p < 0.02).
Discussion: We conclude that, in adolescents, short-term treatment with orlistat, in the context of a behavioral program, is well-tolerated and has a side-effect profile similar to that observed in adults, but its true benefit versus conventional therapy remains to be determined in placebo-controlled trials.